Arnaldo Nakamura

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 5

Top Topics

Dna Damage Response

Signaling Pathway

Bacillus Subtilis

Top Venues

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Jordan D Lewicky, Alexandrine L Martel, Nya L Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, Hoang-Thanh Le
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 14 (12) (2022)
Jordan D Lewicky, Alexandrine L Martel, Nya L Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, Hoang-Thanh Le
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 14 (12) (2022)
Sammy Nyongesa, Philipp M Weber, Eve Bernet, Francisco Pulido, Cecilia Nieves, Marta Nieckarz, Marie Delaby, Tobias Viehboeck, Nicole Krause, Alex Rivera-Millot, Arnaldo Nakamura, Norbert O E Vischer, Michael S VanNieuwenhze, Yves V Brun, Felipe Cava, Silvia Bulgheresi, Frédéric J Veyrier
Evolution of longitudinal division in multicellular bacteria of the Neisseriaceae family. Nature communications 13 (1) (2022)
Jordan D Lewicky, Alexandrine L Martel, Nya L Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, Hoang-Thanh Le
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 14 (12) (2022)
Jordan D Lewicky, Alexandrine L Martel, Nya L Fraleigh, Emilie Picard, Leila Mousavifar, Arnaldo Nakamura, Francisco Diaz-Mitoma, René Roy, Hoang-Thanh Le
Exploiting the DNA Damaging Activity of Liposomal Low Dose Cytarabine for Cancer Immunotherapy. Pharmaceutics 14 (12) (2022)